AIM ImmunoTech Inc.

12/09/2021

today announced that safety data on its drug was recently presented at the Eighth European Scientific Working Group on (ESWI) virtual conference in Salzburg, Austria, on December 4-7, 2021. The conference also included research on -19 and respiratory syncytial virus: https://bit.ly/30b5Is5

12/06/2021

today announced that Thomas Equels, Chief Executive Officer, will be participating in two upcoming investor conferences: https://bit.ly/3rKYAOB

11/24/2021

https://www.bostonherald.com/2021/11/19/long-covid-is-a-public-health-crisis-doctors-say-with-patients-having-severe-symptoms/

Some patients with lingering coronavirus symptoms for weeks or months, otherwise known as long COVID, are experiencing debilitating symptoms that are sometimes ignored in what doctors are calling a…

11/22/2021

explores the long-term effects of infection - called post-acute sequelae of SARS-CoV-2, PASC, or simply : https://www.npr.org/2021/11/19/1057241501/living-with-long-covid

For those living with long COVID, daily activities like going for a walk, washing the dishes, or being on a Zoom call can be incredibly draining. These long-term effects of a COVID infection - called post-acute sequelae of SARS-CoV-2, PASC, or more simply long COVID - have been a reality for many pa...

11/16/2021

announces financial results for the third quarter ended September 30, 2021 and provides a business update: https://bit.ly/30q0Kr6

10/19/2021

announced it has submitted an Investigational New Drug application and an accompanying application for Fast Track status with the for a planned Phase2 study of as a therapy for locally advanced or metastatic late-stage https://bit.ly/3aXDi6p

10/06/2021

today released detailed safety data from a Phase 1 that supports the company’s belief that its drug has significant potential as an intranasal therapeutic for : https://bit.ly/3Dbmtkw

10/04/2021

Inc. today announced that it has finalized the protocol for a planned Phase 2 study of the company’s drug as a therapy for locally advanced or metastatic late-stage . https://bit.ly/3l7i5gg

09/30/2021

announced that AIM and have a signed Clinical Trial Agreement ( ) for a Phase 2a Human Challenge Trial ( ) to test the company’s drug as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and A virus (H3N2): https://bit.ly/2XZQdSf

09/28/2021

today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the for two separate Phase 2 clinical studies to study the potential of as both an infusion and an intranasal therapy for early-onset , the disease caused by SARS-CoV-2: https://bit.ly/3ANPVws

09/27/2021

files provisional application for as an early-onset intranasal therapy that may also confer enhanced immunity to a wide range of respiratory viruses: https://bit.ly/2Y4Jc2P

09/23/2021

New York Times - "This is really scary:" Kid Struggle with Long COVID

Lingering physical, mental and neurological symptoms are affecting children as well as adults, including many who had mild reactions to the initial coronavirus infection.